Grufity logoGrufity logo

BIIB

298.90USD-2.95(-0.98%)Market Closed

Biogen Inc

Market Summary

USD298.90-2.95Market Closed
-0.98%

BIIB Alerts

BIIB Stock Price

RSI Chart

Valuation

Market Cap

41.3B

Price/Earnings

14.4

Price/Sales

3.98

Price/Cashflow

17.21

MarketCap/EBT

12.16

Price/Sales

Profitability

EBT Margin

32.74%

Return on Equity

22.44%

Return on Assets

11.53%

Fundamentals

Revenue

Revenue (TTM)

10.4B

Revenue Y/Y

-9.73%

Revenue Q/Q

-3.11%

Earnings

Earnings (TTM)

2.9B

Earnings Y/Y

244.68%

Earnings Q/Q

7.25%

Price Action

52 Week Range

187.16311.88
(Low)(High)

Last 7 days

-2.1%

Last 30 days

7.4%

Last 90 days

52.5%

Trailing 12 Months

30.8%

Financial Health

Current Ratio

2.49

Debt/Equity

0.49

Debt/Cashflow

0.38

Investor Care

Buy Backs (1Y)

1.97%

Diluted EPS (TTM)

19.64

Peers (Alternatives to Biogen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Biogen

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-2.5%10,36310,63410,82010,98211,101
  S&GA Expenses-3.4%2,5592,6502,7142,6742,693
Earnings Before Taxes46.7%3,3932,3131,6261,7451,693
Net Income39.1%2,8652,0591,4501,5561,546
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.9%24,85425,08123,61423,87723,807
  Current Assets0.3%9,7669,7417,9167,8577,162
    Cash Equivalents38.9%3,6762,6471,7492,2611,542
  Inventory6.2%1,3751,2941,2151,3521,348
  Net PPE-2.6%3,2663,3553,3733,4163,411
  Goodwill-0.1%5,7415,7505,7585,7615,761
Liabilities-8.6%12,08713,21812,39412,91812,925
  Current Liabilities-21.8%3,9265,0183,9474,2984,212
  Long Term Debt0.0%6,2796,2776,2766,2746,272
Shareholder's Equity7.5%12,76711,87311,24210,89610,430
  Retained Earnings6.4%15,91614,96014,21613,91213,544
  Additional Paid-In CapitalNaN%--11968-
Accumulated Depreciation-2,007----
Shares Outstanding-0.8%146147148--
Minority Interest4.4%-8.70-9.10-21.6064452
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.7%2,3982,5423,0333,6402,435
  Share Based Compensation1122.2%13211132396
Cashflow From Investing633.6%1,605-300.80-1,147.00-563.70-617.40
Cashflow From Financing-41.3%-1,730.10-1,224.70-1,317.70-2,086.20-2,497.10
  Buy Backs-40.0%7501,2501,2001,8002,200

Risks

What is the probability of a big loss on BIIB?

90.8%


Probability that Biogen stock will be more than 20% underwater in next one year

56.5%


Probability that Biogen stock will be more than 30% underwater in next one year.

15%


Probability that Biogen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIIB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biogen was unfortunately bought at previous high price.

Returns

Cumulative Returns on BIIB

7.9%


10-Year Cumulative Returns

1.9%


7-Year Cumulative Returns

-1.3%


5-Year Cumulative Returns

0.9%


3-Year Cumulative Returns

What are the long-term rolling returns for BIIB?

FIve years rolling returns for Biogen.

Which funds bought or sold BIIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
424,000
424,000
0.44%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-9.43
7,765
51,000
0.03%
2022-11-23
Toroso Investments, LLC
REDUCED
-2.88
647,000
3,030,000
0.13%
2022-11-22
CVA Family Office, LLC
ADDED
50
14,000
28,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
3,614,000
3,614,000
0.04%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
0.07
269,000
1,135,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.76
15,381,000
66,787,000
0.11%
2022-11-21
Bray Capital Advisors
UNCHANGED
-
2,000
7,000
-%
2022-11-21
FourThought Financial, LLC
REDUCED
-85.12
-20,000
5,000
-%
2022-11-18
Industrial Alliance Investment Management Inc.
ADDED
195.43
6,282,000
8,472,000
0.25%

1–10 of 45

Latest Funds Activity

Are funds buying BIIB calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BIIB

Biogen News

StockNews.com

BIIB: 3 Stocks You'll Regret Not Buying This Year.38 hours ago

BIIB Fair Value

Recent SEC filings of Biogen

View All Filings
Date Filed Form Type Document
Nov 21, 2022
3
Insider Trading
Nov 10, 2022
8-K
Current Report
Oct 28, 2022
4
Insider Trading
Oct 25, 2022
8-K
Current Report
Oct 25, 2022
10-Q
Quarterly Report
Sep 06, 2022
4
Insider Trading
Aug 31, 2022
4
Insider Trading

Latest Insider Trading transactions for BIIB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-27
ALEXANDER SUSAN H
SOLD
-1,552,830
280.7
-5,532
EVP Chief Legal Off & Corp Sec
2022-09-01
MCDONNELL MICHAEL R
SOLD (Taxes)
-485,090
199.79
-2,428
EVP, Chief Financial Officer
2022-09-01
MCDONNELL MICHAEL R
ACQUIRED
-
-
4,746
EVP, Chief Financial Officer
2022-08-01
Murphy Nicole
ACQUIRED
-
-
1,080
Head of Pharm Ops and Tech
2022-08-01
Murphy Nicole
SOLD (Taxes)
-66,753.9
209.26
-319
Head of Pharm Ops and Tech
2022-07-01
Izzar Rachid
ACQUIRED
-
-
504
Head of Alzheimer's Disease
2022-07-01
Izzar Rachid
SOLD (Taxes)
-31,173.2
210.63
-148
Head of Alzheimer's Disease
2022-07-01
Kramer Robin
ACQUIRED
-
-
252
Chief Accounting Officer
2022-07-01
Kramer Robin
SOLD (Taxes)
-15,586.6
210.63
-74
Chief Accounting Officer
2022-06-15
Rowinsky Eric K
ACQUIRED
-
-
1,370
-

1–10 of 50

Michel Vounatsos
9610
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Income Statement

2022-09-30
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total revenue$ 2,508.5$ 2,778.9$ 7,629.4$ 8,247.9
Cost and expenses:    
Cost of sales, excluding amortization and impairment of acquired intangible assets469.5511.81,707.41,449.6
Research and development549.2702.41,629.51,801.7
Selling, general and administrative563.3654.11,770.81,886.4
Amortization and impairment of acquired intangible assets56.5111.0190.9813.2
Collaboration profit (loss) sharing45.321.2(42.6)74.5
(Gain) loss on fair value remeasurement of contingent consideration(2.1)(15.6)(13.7)(49.1)
Acquired in-process research and development0.00.00.018.0
Restructuring charges15.40.0124.10.0
Gain on sale of building(503.7)0.0(503.7)0.0
Other (income) expense, net(56.0)502.9(221.3)913.4
Total cost and expense1,137.42,487.84,641.46,907.7
Income before income tax expense and equity in loss of investee, net of tax1,371.1291.12,988.01,340.2
Income tax (benefit) expense236.2(25.9)578.5(390.7)
Equity in (income) loss of investee, net of tax0.0(1.1)(2.6)(17.2)
Net income1,134.9318.12,412.11,748.1
Net income (loss) attributable to noncontrolling interests, net of tax0.2(11.1)(84.4)560.2
Net income attributable to Biogen Inc.$ 1,134.7$ 329.2$ 2,496.5$ 1,187.9
Net income per share:    
Basic earnings per share attributable to Biogen Inc.$ 7.86$ 2.22$ 17.12$ 7.93
Diluted earnings per share attributable to Biogen Inc.$ 7.84$ 2.22$ 17.07$ 7.90
Weighted-average shares used in calculating:    
Basic earnings per share attributable to Biogen Inc.144,400148,000145,800149,900
Diluted earnings per share attributable to Biogen Inc.144,800148,600146,200150,300
Product, net    
Total revenue$ 1,962.1$ 2,205.7$ 6,083.3$ 6,653.4
Revenue from anti-CD20 therapeutic programs    
Total revenue416.9415.41,252.61,244.4
Other    
Total revenue$ 129.5$ 157.8$ 293.5$ 350.1

BIIB Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,675.6$ 2,261.4
Marketable securities1,235.51,541.1
Accounts receivable, net1,568.81,549.4
Due from anti-CD20 therapeutic programs415.4412.3
Inventory1,375.01,351.5
Other current assets1,495.5740.8
Total current assets9,765.87,856.5
Marketable securities860.3892.0
Property, plant and equipment, net3,266.43,416.4
Operating lease assets424.5375.4
Intangible assets, net2,008.92,221.3
Goodwill5,741.25,761.1
Deferred tax asset1,174.51,415.1
Investments and other assets1,612.61,939.5
Total assets24,854.223,877.3
Current liabilities:  
Current portion of notes payable0.0999.1
Taxes payable237.3174.7
Accounts payable383.2589.2
Accrued expense and other3,305.92,535.2
Total current liabilities3,926.44,298.2
Notes payable6,279.26,274.0
Deferred tax liability328.9694.5
Long-term operating lease liabilities354.8330.4
Other long-term liabilities1,198.11,320.5
Total liabilities12,087.412,917.6
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity  
Preferred stock, par value $0.001 per share0.00.0
Common stock, par value $0.0005 per share0.10.1
Additional paid-in capital0.068.2
Accumulated other comprehensive income (loss)(163.6)(106.7)
Retained earnings15,916.113,911.7
Treasury stock, at cost(2,977.1)(2,977.1)
Total Biogen Inc. shareholders’ equity12,775.510,896.2
Noncontrolling interests(8.7)63.5
Total equity12,766.810,959.7
Total liabilities and equity$ 24,854.2$ 23,877.3